Home » Fact Sheet » Clinically extremely vulnerable, COVID 19 infection and breastfeeding

Clinically extremely vulnerable, COVID 19 infection and breastfeeding

Because I am immunocompromised myself, I am all too well aware of the information on protection from COVID 19 including the recommendations launched in December 2021 by the government on sotrovimab (Xevudy) and molnupiravir (Lagevrio) . This may affect some breastfeeding mothers e.g. those with IBD or on biologicals for other reasons . There are no simple answers but this is the information I have been able to find in one place. The factsheet was updated in April 2022 following the licence change by the FDA of sotrovimab, and added data on Evusheld and remdesivir .

Clinically extremely vulnerable, COVID 19 infection and breastfeeding factsheet